

Oppervlakkig Flebitis: het kleine venijn

Dr. Jürgen Verbist

Thoraco-Vasculaire Heelkunde


Imeldaziekenhuis

Bonheiden

Diagnose

- Wat?







weighted mean prevalence

DVT	18.2%	(95% CI 12.2 - 26.3%)*
helft in continuïteit, helft op afstand		
PE	8.2%	(95% CI 3.3 - 18.9%)

10,2 % bijkomende thrombo-embolische events binnen 3 m**

Recommendation 43

For patients with suspected lower limb superficial vein thrombosis, **a whole leg ultrasound scan is recommended** to determine thrombus extent and exclude asymptomatic deep vein thrombosis.

Class	Level	References
I	B	Decousus e.a. (2010)** Di Minno e.a. (2016)* Jorgensen e.a. (1993)

S. Kakkos e.a. "European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis" Eur J Endovasc Surg (2021) 61, 9-82

Diagnose

- Wat?

- Duplex van het hele lidmaat

- bevestigen diagnose
 - uitsluiten DVT
 - bepalen lokalisatie en uitgebreidheid
 - opsporen onderliggende oorzaak (veneuze insufficiëntie)
 - uitgangspunt voor opvolging van evolutie

Diagnose

- Waarom?

- Veneuze insufficiëntie
- Trauma
- Onbekend

- **Verdacht:** bilateraal, recurrent, ...


- thrombofilie, Buerger, ...

(jonge patiënt)

- paraneoplastisch, ...


(oudere patiënt)

Behandeling



Oorzaak?

- Verdacht
- Veneuze insufficiëntie



Suspected SVT lower limb

Whole leg US

DVT

SVT

Something else

suspicious

< 3 cm to the deep vein


> 3 cm to the deep vein

> 5 cm in length

< 5 cm in length

Therapeutic anticoagulation

Recommendation 48		
For patients with lower limb superficial vein thrombosis < 3 cm from the junction with the deep veins, therapeutic anticoagulation is recommended.		
Class	Level	References
I	C	Consensus



Suspected SVT lower limb

Whole leg US

Recommendation 49		
For patients with lower limb superficial vein thrombosis, which exhibits high risk clinical and/or anatomical features, a 3 month course of anticoagulation may be considered.		
Class	Level	References
IIb	C	Nikolakopoulos e.a. (2018)

DVT

SVT

Something else

suspicious


< 3 cm to the deep vein


> 3 cm to the deep vein

> 5 cm in length

< 5 cm in length

Therapeutic anticoagulation for 3 months





Suspected SVT lower limb

Whole leg US

DVT

SVT

Something else

suspicious

< 3 cm to the deep vein

> 3 cm to the deep vein

> 5 cm in length

< 5 cm in length


Therapeutic anticoagulation
for 3 months

Fondaparinux 2,5 mg 1/d

Recommendation 45

For patients with suspected lower limb superficial vein thrombosis > 3 cm away from the junction with the deep veins and extending > 5 cm in length, **fondaparinux 2.5 mg once daily** is recommended.

Class	Level	References
I	B	Decousus e.a. (2010)



Suspected SVT lower limb

Whole leg US

DVT

SVT

suspicious

< 3 cm to the deep vein

> 3 cm to the deep vein

> 5 cm in length

< 5 cm in length

Therapeutic anticoagulation for 3 months

Fondaparinux 2,5 mg 1/d or intermediate dose LMWH

Recommendation 46

For patients with lower limb superficial vein thrombosis > 3 cm away from the junction with the deep veins and extending > 5 cm in length, an intermediate dose of a LMWH should be considered as an alternative to fondaparinux.

Class	Level	References
Ila	B	Decousus e.a. (2010) Cosmi e.a. (2010) Duffett e.a. (2019)

something else

Red background area containing the text: Therapeutic anticoagulation for 3 months

Orange background area containing the text: Fondaparinux 2,5 mg 1/d or intermediate dose LMWH

Suspected SVT lower limb

Whole leg US

DVT

SVT

suspicious

< 3 cm to the deep vein

> 3 cm to the deep vein

> 5 cm in length

< 5 cm in length

Therapeutic anticoagulation for 3 months

Fondaparinux 2,5 mg 1/d or intermediate dose LMWH

What about DOACs ?

SURPRISE phase 3b trial

RCT Rivaroxaban 10 mg/d during 45 days
Fondaparinux 2.5 mg/d

Non-inferior efficacy and safety
off-label use

Beyer-Westendorf e.a., Lancet Haematol 2017

Something else

Suspected SVT lower limb

Whole leg US

DVT

SVT

Something else

suspicious

< 3 cm to the deep vein

> 3 cm to the deep vein



> 5 cm in length


< 5 cm in length

Therapeutic anticoagulation for 3 months

Fondaparinux 2,5 mg 1/d or intermediate dose LMWH for 45 days

Recommendation 47		
For patients with lower limb superficial vein thrombosis > 3 cm from the junction with the deep veins and extending > 5 cm in length on ultrasound, 45 days of anticoagulation treatment is recommended.		
Class	Level	References
I	B	Decousus e.a. (2010) Cosmi e.a. (2012)





Suspected SVT lower limb

Whole leg US

DVT

SVT

suspicious

< 3 cm to the deep vein

> 3 cm to the deep vein

> 5 cm in length

< 5 cm in length

Therapeutic anticoagulation for 3 months

Fondaparinux 2,5 mg 1/d or intermediate dose LMWH for 45 days

No anticoagulation

Recommendation 44

For patients with isolated lower limb superficial vein thrombosis < 5cm in length on ultrasound and lacking high risk features, such as malignancy, thrombophilia or proximity to the deep venous system, anticoagulation is not recommended.


Class	Level	References
III	C	consensus

Something else

Red background area containing the text 'Therapeutic anticoagulation for 3 months'.

Orange background area containing the text 'Fondaparinux 2,5 mg 1/d or intermediate dose LMWH for 45 days'.

Yellow background area containing the text 'No anticoagulation'.







SomeScope
Date: 8/23/2018 11:00:00
Time: 11:00:00
Gain: 70
Depth: 160/2
Focus: 10
Filter: 5
Scale: 55-100

ATRIUM